Andarine (S4)
A selective androgen receptor modulator whose development was abandoned due to vision side effects.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Andarine (S4)
A selective androgen receptor modulator whose development was abandoned due to vision side effects.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
Andarine (S4, GTX-007) is a selective androgen receptor modulator originally developed by GTx, Inc. for musculoskeletal diseases and benign prostatic hyperplasia. Clinical development was abandoned after preclinical identification of visual side effects (night blindness, yellow tint to vision) linked to ocular androgen receptor binding. No Phase I human trials published.
Benefits reported in the imported source
- Preclinical anabolic effects in muscle and bone
- Potent lean mass and fat loss in animal models
Risks and limits
- Development abandoned due to vision side effects (night blindness, yellow tinting)
- No published Phase I human trials
- Binding to ocular androgen receptors causes visual disturbances
Source bottom line: Preclinical only; clinical development halted due to reversible but significant vision effects.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — S4 (Andarine) Guide for Beginners: Benefits, Risks, Dosage and Stacks
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A fitness guide describes andarine protocols ranging from 25 to 75 mg per day, with 50 mg daily or less noted as ideal for most users, divided into two equal doses due to the compound's 3-6 hour half-life.
S4 (Andarine) Guide for Beginners: Benefits, Risks, Dosage and Stacks
Unverified imported account — Andarine S4 - Guide to Effects, Dosing, Cycles and Side Effects
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A supplement resource documents andarine cutting protocol of 25 mg daily for 6-8 weeks, and bulking protocols using 50 mg of andarine for 8 weeks, with advanced users potentially extending cycles to 10 weeks if post-cycle therapy is planned.
Andarine S4 - Guide to Effects, Dosing, Cycles and Side Effects
Unverified imported account — Andarine S4 Complete Guide: Benefits, Uses, Dosage (2026)
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A fitness reference documents andarine dosing of 30 mg daily divided into three 10 mg portions, or 50 mg daily for advanced users, cycled for 8 to 12 weeks, with a note that post-cycle therapy is recommended after use.
Andarine S4 Complete Guide: Benefits, Uses, Dosage (2026) (availability check 2026-10-15: source not retrieved; HTTP 403)
Pharmacokinetic context
Historical half-life estimate: 3–6 hours. Gao, Kim & Dalton 2006, Pharm Res 23(8):1641-1658, PMID 16841196 — rats and dogs only, no human PK trial exists Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- S4 (Andarine) SARM - MorePlatesMoreDates
- Selective Androgen Receptor Modulator for Prostate - ClinicalTrials.gov (availability check 2026-10-15: response exceeded review limit; not fully inspected; HTTP 200)
Snapshot provenance
Source ID: catalog:hormone:andarine. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.